A 12-Week Multicenter, 2-Arm Regimen, Exploratory Study to Evaluate the Tolerability and Safety of Valsartan Administered Once Daily vs Daily, in Patients With Stable, Chronic Heart Failure (NYHA Class Ll-lll).
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2011
At a glance
- Drugs Valsartan (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions
- Acronyms DESTINY-HF
- Sponsors Novartis
- 07 Jun 2011 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
- 29 May 2007 Status change
- 22 Mar 2006 New trial record.